The Global Psilocybin Decriminalisation Landscape

Over the past decade, the global policy landscape surrounding psilocybin has shifted dramatically. Once universally relegated to the strictest tiers of drug prohibition, psilocybin is increasingly the subject of novel legislative models. These range from the outright deprioritisation of criminal penalties for personal use to tightly controlled medical access frameworks. As jurisdictions experiment with alternatives to traditional prohibition, a complex patchwork of laws has emerged. For South Africans, where psilocybin remains a Schedule 7 substance under the Medicines and Related Substances Act, understanding these international models provides useful context for ongoing debates about domestic drug policy reform.

Decriminalisation versus Regulated Access

Before examining specific regions, it is helpful to distinguish between two fundamentally different policy approaches: decriminalisation and regulated access. Decriminalisation generally refers to the removal of criminal penalties for the personal possession of a substance. Under decriminalisation, the substance remains illegal, and civil fines or confiscation may still apply, but individuals are not prosecuted or incarcerated. It does not create a legal supply chain.

In contrast, regulated access (or legalisation) involves creating a legal, state-oversight framework for the production, distribution, and consumption of a substance. This approach is often highly medicalised, restricting access to clinical settings, though some models allow for broader adult use. Both approaches aim to mitigate the harms of strict prohibition, but they operate on very different principles and scales of government involvement.

The United States: State-Level Innovation

In the absence of federal reform, individual US states have become laboratories for psychedelic policy. In 2020, Oregon became the first state to pass a regulated access measure. The legislation legalised psilocybin for adults to consume in licensed, supervised service centres. The programme is overseen by the Oregon Health Authority, which licenses facilitators and regulates the production of the substance, though it does not require a medical prescription for access.

Colorado followed suit in 2022 with a proposition that decriminalises the personal use, sharing, and cultivation of psilocybin for adults, while also establishing a framework for licensed 'healing centres' regulated by the state. Additionally, several US municipalities—including Denver, Washington D.C., and parts of California—have passed local decriminalisation measures that simply make personal use the lowest law enforcement priority. These models represent a dual-track approach: reducing criminal penalties for personal use while building a formal, commercial infrastructure for therapeutic access.

Australia: The Medicalised Model

Australia has taken a distinctly clinical route. In 2023, the Therapeutic Goods Administration (TGA), the country's medicines regulator, reclassified psilocybin from a prohibited substance to a Schedule 8 controlled drug. This means psilocybin can be legally prescribed by authorised psychiatrists for specific, treatment-resistant mental health conditions, such as treatment-resistant depression.

Unlike the US state models, Australia's approach does not decriminalise personal possession outside of a clinical setting; it remains illegal. The TGA's decision was specifically designed to integrate psilocybin into the conventional medical system, requiring strict clinical oversight and pharmaceutical-grade supply, rather than allowing broader adult access or state-licensed service centres.

Europe: Tolerance and Medical Pathways

In Europe, the landscape is characterised by historic tolerance and emerging clinical pathways. The Netherlands famously tolerates the sale and use of 'magic truffles' (the underground sclerotia of psilocybin-containing fungi), which exist in a legal grey area, while the mushrooms themselves are prohibited. This model relies on regulatory tolerance rather than explicit legalisation.

Conversely, Portugal decriminalised the personal possession of all drugs, including psilocybin, in 2001. Under the Portuguese model, individuals found in possession of small quantities are referred to local health commissions rather than facing criminal prosecution. Other European nations, such as the United Kingdom and Germany, maintain strict prohibitions on psilocybin, though they are increasingly hosting clinical trials to explore its medical potential.

Implications for South Africa

These global models offer contrasting blueprints for South African policymakers. Currently, psilocybin is a Schedule 7 substance under the Medicines and Related Substances Act, meaning it is completely prohibited with no accepted medical use. Any shift in policy would involve the South African Health Products Regulatory Authority (SAHPRA). A medicalised route, akin to Australia’s TGA model, would require robust clinical evidence and a formal rescheduling process.

Alternatively, a decriminalisation model would require legislative reform similar to the debates surrounding cannabis. While the Constitutional Court of South Africa previously ruled on the right to cultivate and consume cannabis in private, the pharmacological and legal distinctions between cannabis and psilocybin mean that the precedent does not directly transfer. As global evidence on the public health impacts of these various models continues to accumulate, they provide a framework for evaluating how South Africa might reconsider its own approach to psychedelic substances.